|
|
- The company has poor fundamentals for a short-term investment strategy.
|
|
|
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The stock is in a well-established, long-term rising trend above the technical support level at 70.34 USD
|
|
|
- Stock prices approach a strong long-term resistance in weekly data at USD 97.13.
- The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
- The firm trades with high earnings multiples: 44.87 times its 2021 earnings per share.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last few months, analysts have been revising downwards their earnings forecast.
|
|
|
|
|
|
|
| Sales 2021 |
1 221 M
-
-
|
| Net income 2021 |
212 M
-
-
|
| Net cash 2021 |
1 151 M
-
-
|
| P/E ratio 2021 |
44,9x |
| Yield 2021 |
0,98% |
|
| Capitalization |
9 450 M
9 450 M
-
|
| EV / Sales 2021 |
6,79x |
| EV / Sales 2022 |
6,13x |
| Nbr of Employees |
2 289 |
| Free-Float |
63,4% |
|
Upcoming event on DOLBY LABORATORIES, INC.
Notations Surperformance© Fundamental ratings
|
Overall rating |
| Trading Rating |
|
| Investor Rating |
|
| Growth (Revenue) |
|
| Valuation |
- |
| Finances |
- |
| Profitability |
|
| Earnings quality |
|
| Business Predictability |
|
| P/E ratio |
|
| Potential |
|
| Yield |
|
| Consensus |
|
| 7 days EPS revision |
|
| 4 months EPS revision |
|
| 1 year EPS revision |
|
| 4 months Revenue revision |
|
| 1 year Revenue revision |
|
Technical ratings
| Short Term Timing |
|
| Middle Term Timing |
|
| Long Term Timing |
|
| RSI |
|
| Bollinger Spread |
|
| Unusual Volumes |
|
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
